Sawyer Adam, McGoldrick R B, Mackey S P, Allan R, Powell B
Melanoma Unit, St. George's Hospital, Blackshaw Road, Tooting, London SW17 0QT, UK.
J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):453-6. doi: 10.1016/j.bjps.2007.11.024. Epub 2008 May 12.
Histological confirmation and assessment of Breslow thickness are essential before embarking on the management plan in Malignant Melanoma (MM). Computerised Tomography (CT) is used in staging of MM in the UK according to BAD/BAPS (British Association of Dermatologists/British Association of Plastic Surgeons). Currently UK guidelines for the management of cutaneous melanoma at intermediate or high risk of recurrent disease (American Joint Cancer Committee) AJCC IIB disease or worse (Breslow 2.01-4.0mm with ulceration or Breslow >4mm) should have the following staging investigations: chest X-ray; liver ultrasonography or computed tomographic (CT) scan with intravenous contrast enhancement of chest, abdomen and pelvis; liver function tests; lactate dehydrogenase and full blood count. It has been the practice at our unit to perform a CT head and neck also as part of our staging. The aim of this study was to determine whether CT staging changed clinical management at the initial presentation scan and follow up scans. Also we aimed to see whether there was a benefit in performing CT head and neck in staging.
A retrospective case note review was performed to see whether CT staging actually changed patient clinical management on 132 cases of AJCC IIB melanoma or worse over the past six years at our unit. Clinical management changes were divided into two groups: Initial presentation CT staging and follow up CT staging. In addition numbers of metastases to body regions were recorded.
A total of 488 CT scans were performed on 132 patients (3.7 scans per patient). Initial presentation CT staging scans picked up 1/132 (0.7%) patient with an occult metastases that changed their clinical management. Of the 356 follow up CT staging scans imaging (11/127) 8.6% of patients had metastases detected and clinical management changed. All of these patients exhibited symptoms and signs of clinical metastatic disease. Head metastases are at least as common as other regions such as the chest & abdomen and more common than in the pelvis. Neck CT did not change management.
CT staging for cutaneous melanoma is not indicated unless there are signs or symptoms of metastatic disease. If there are symptoms and signs of metastatic disease than patients should be staged and we advocate that staging of AJCC IIB/C should include imaging of the head in addition to chest, abdomen and pelvis.
在制定恶性黑色素瘤(MM)的治疗方案之前,进行组织学确诊和评估Breslow厚度至关重要。在英国,根据英国皮肤科医师协会/英国整形外科医师协会(BAD/BAPS)的标准,计算机断层扫描(CT)用于MM的分期。目前,英国针对复发性疾病中高危(美国癌症联合委员会)AJCC IIB期及以上(Breslow厚度2.01 - 4.0mm伴溃疡或Breslow厚度>4mm)皮肤黑色素瘤的管理指南要求进行以下分期检查:胸部X光检查;肝脏超声检查或胸部、腹部和骨盆静脉造影增强的计算机断层扫描(CT);肝功能检查;乳酸脱氢酶和全血细胞计数。我们科室的惯例是将头部和颈部CT检查也作为分期的一部分。本研究的目的是确定CT分期在初次扫描和随访扫描时是否改变了临床治疗方案。此外,我们还旨在了解在分期中进行头部和颈部CT检查是否有益。
对我们科室过去六年中132例AJCC IIB期或更晚期黑色素瘤患者的病历进行回顾性研究,以确定CT分期是否实际改变了患者的临床治疗方案。临床治疗方案的改变分为两组:初次扫描CT分期和随访CT分期。此外,记录身体各部位转移灶的数量。
132例患者共进行了488次CT扫描(每位患者平均3.7次)。初次扫描CT分期发现1/132(0.7%)例患者存在隐匿性转移灶,从而改变了其临床治疗方案。在356次随访CT分期扫描中,有11/127(8.6%)例患者检测到转移灶并改变了临床治疗方案。所有这些患者均表现出临床转移疾病的症状和体征。头部转移灶与胸部和腹部等其他部位的转移灶一样常见,且比骨盆部位的转移灶更常见。颈部CT检查未改变治疗方案。
除非有转移疾病的症状或体征,否则不建议对皮肤黑色素瘤进行CT分期。如果有转移疾病的症状和体征,则应对患者进行分期,我们主张AJCC IIB/C期的分期除了包括胸部、腹部和骨盆的成像外,还应包括头部成像。